IOT Innovotech Inc.
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; antimicrobial and anti-biofilm materials; BEST assay testing; implanted medical devices testing; bacteriophage testing; and analytical services. The company serves customers in the sector of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food. Innovotech Inc. is headquartered in Edmonton, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Innovotech (CVE: IOT)
›
Innovotech (CVE: IOT) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0650 CAD on 19 November 2026, down 67.5% over 52 weeks. Its 52-week range is 0.0600 CAD to 0.2900 CAD: the price is 77.6% below the high and 8.3% above the low.
Its market capitalisation is 3.54M CAD.
Innovotech reports return on equity of 2.6%, an operating margin of -41.7% and revenue down 47.8% year over year.
Its debt exceeds its cash by 233.94K CAD, a debt-to-equity ratio of 0.04. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 30 March 2027.